# Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer

> **NCT01482728** · EARLY_PHASE1 · COMPLETED · sponsor: **University of Virginia** · enrollment: 12 (actual)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT01482728
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2015-05
- **Final completion:** 2015-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2016-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01482728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01482728, "Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01482728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*